



Medinice S.A.  
ul. Stefana Hankiewicza 2  
02-103 Warsaw, Poland

23 JANUARY 2026.

**CURRENT REPORT NO. 4 / 2026**  
**DATED 23 JANUARY 2026 R.**

**Title: Signing of a letter of intent regarding the commercialization of CoolCryo**

Legal basis: Article 17 section 1 of the MAR Regulation – inside information

The Management Board of Medinice S.A. (the "Company") announces that on January 22, 2026, the Company signed a Letter of Intent ("LoI") with an international entity active in the cardiac surgery market, concerning the potential sale of the CoolCryo project.

According to the LoI, the planned transaction would include the sale of rights to the CoolCryo project along with global patent protection, with a particular focus on the territories of Europe and the United States.

The detailed terms of the transaction, including the final sales price and payment terms, will be specified in the definitive agreement. The parties have agreed to make every effort to conclude the final agreement within 3 months of the signing of the LOI.

This information is being provided because the ongoing negotiations may result in significant changes to the Issuer's asset structure, which could potentially have a significant impact on its financial situation and asset valuation.

The company will inform about any further material arrangements regarding the transaction in question by means of relevant current reports, should such an information disclosure obligation arise.

*Patient friendly smart routing  
therapies for quality of life*

**Medinice S.A.**  
biuro@medinice.pl  
www.medinice.pl